Le Lézard
Classified in: Health
Subjects: DIS, DEI

Atlanta Raising Awareness for Nation's No. 1 Cause of Disability - Arthritis


ATLANTA, Feb. 16, 2022 /PRNewswire/ -- More than 500 people in Atlanta are supporting the Arthritis Foundation's mission to cure arthritis and help people with arthritis live a full life by participating in the Atlanta Walk to Cure Arthritis on Saturday, May 7th at Brook Run Park.

Walk to Cure Arthritis, the Arthritis Foundation's annual, flagship fundraising event, is the largest arthritis gathering in the world. It is where communities join together nationwide to see the power of LIVING YES, celebrate Arthritis Warriors and connect with others in the community ? while raising funds for research, resources and a cure. The Arthritis Foundation is dedicated to helping people with arthritis be a Champion of Yes by giving them the tools and resources they need to live a full life. This year, the community will come together to help support the 1 in 4 Americans living with arthritis ? including 1.8 million Georgians.

"We can all make a difference in the lives of people with arthritis ? the No. 1 cause of disability," said Stuart Winborne, Georgia Executive Director. "For 70 years, the Arthritis Foundation has committed to conquering this disease through life-changing educational programs and events like the walk."

Get more information and learn more about registering for the Atlanta Walk by visiting www.walktocurearthritis.org/atlanta or contacting Stuart at [email protected].

About the Arthritis Foundation
The Arthritis Foundation is the Champion of Yes. Leading the fight for the arthritis community, the Foundation helps conquer everyday battles through life-changing information and resources, access to optimal care, advancements in science and community connections. The Arthritis Foundation's goal is to chart a winning course, guiding families in developing personalized plans for living a full life ? and making each day another stride towards a cure. Visit their website at www.arthritis.org.

SOURCE The Arthritis Foundation - Georgia


These press releases may also interest you

at 02:07
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....

at 02:05
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces the opening of its proposed $100 million tender offer (the "Tender...

at 01:30
Urinary Catheters Market size is set to grow by USD 2.44 bn from 2024-2028, rising geriatric population with urinary incontinence to boost the market growth, Technavio
The global urinary catheters market  size is estimated to grow by USD 2.44 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 7.63%  during the forecast period. ...

at 00:25
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Zai Lab Limited and Innoviva Specialty Therapeutics today announced that China's National Medical Products Administration (NMPA) has approved Zai Lab's New Drug Application (NDA) for XACDURO® (sulbactam-durlobactam) for the treatment of...

19 mai 2024
Subang Jaya Medical Centre Applauded by Frost & Sullivan as the Best Hospital Company of the Year in Malaysia for the fourth consecutive year
Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its...

19 mai 2024
Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC)
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

More news about Health...


News published on and distributed by: